Results 21 to 30 of about 4,977 (213)

Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT Machine learning (ML)–based methods have been proposed as a potential approach for identifying candidate drugs to be repurposed as disease‐modifying treatments for Parkinson's disease (PD). We applied an ML‐based signal detection method to identify drugs associated with PD and evaluated the method's generalizability.
Pylkkö E, Courtois É, Paakinaho A, Hartikainen S, Kaasinen V, Elbaz A, Thiébaut ACM, Ahmed I, Tolppanen AM.   +8 more
europepmc   +2 more sources

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. [PDF]

, 2015
Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing.
Albertson, Timothy E, Harper, Richart, Murin, Susan, Sandrock, Christian   +3 more
core   +1 more source

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. [PDF]

, 2011
BACKGROUND: Interactions between spirometry and patient-reported outcomes in COPD are not well understood. This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes in health status with ...
Bourbeau, J, Capkun-Niggli, G, Cerulli, A, Jones, PW, Westwood, M, Worthy, G   +5 more
core   +2 more sources

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD : a systematic review and meta-analysis [PDF]

, 2017
Acknowledgments The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing
Altman, Pablo, Anzueto, Antonio, Bader, Giovanni, Fogel, Robert, Kostikas, Konstantinos, Patalano, Francesco, Price, David B, Rodrigo, Gustavo J, Singh, Dave   +8 more
core   +2 more sources

A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011 [PDF]

, 2013
Background and objective: The Global initiative for chronic Obstructive Lung Disease(GOLD) Committee has proposed a chronic obstructive pulmonary disease (COPD) assessment framework focused on symptoms and on exacerbation risk. This study will evaluate a
Betsuyaku, T, Fujimoto, K, Hagan, G, Hitosugi, H, James, M, Jones, PW, Kato, M, Kobayashi, A   +7 more
core   +1 more source

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study [PDF]

, 2018
Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive ...
Birk, Ruby, Brealey, Noushin, Bremner, Peter R, Ismaila, Afisi S, Lipson, David A, Zhu, Chang-Qing   +5 more
core   +2 more sources

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD

Фармакоэкономика, 2017
In accordance with currently accepted recommendations for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), both monotherapy with long-acting anticholinergics (LAAC) or combined therapy (LAAC / long-acting beta-agonists, LABA ...
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov   +3 more
doaj   +1 more source

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. [PDF]

, 2014
BACKGROUND: Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving quality of life and preventing or treating exacerbations.Treatment tends to begin with one inhaler, and additional therapies ...
Aalbers, Abrahams, Abrahams, Adams, Agusti, Allegra, Ambrosino, Amgott, Anderson, Anonymous, Anthonisen, Antoniu, Anzueto, Anzueto, Appleton, Arievich, Auffarth, Bale, Barnes, Barnes, Barnes, Barr, Bateman, Bateman, Bateman, Bateman, Bateman, Bateman, Bateman, Bateman, Bateman, Baumgartner, Beeh, Beeh, Beeh, Berger, Bleecker, Bleecker, Bleecker, Bogdan, Bogdan, Bourbeau, Bourbeau, Braido, Briggs, Briggs, Briggs, Briggs, Brightling, Brusasco, Brusasco, Buhl, Buhl, Burge, Burge, Burge, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley PMA (on behalf of the Symbicort® study group), Calverly, Calverly, Campbell, Campbell, Casaburi, Cazzola, Cazzola, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Chan, Chapman, Chavannes, Chavannes, Chavannes, Chong, Choudhury, Chuck, Cipriani, Claverley, Cooper, Cooper, Cooper, Cooper, Cope, Cope, Corhay, Corhay, Covelli, Crim, Culpitt, D'Amato, D'Urzo, D'Urzo, D'Urzo, D'Urzo, D'Urzo, D'Urzo, Dahl, Dahl, Dahl, Dahl, Dahl, Dahl, Dahl, Dal Negro, Dal Negro, Dalal, Dalal, Dawber, Decramer, Decramer, Decramer, Decramer, Decramer, Decramer, Decramer, Decramer, Decramer, Decramer, Derenne, Dias, Dias, Dias, DiSantostefano, Doherty, Doherty, Doherty, Doherty, Dong, Donohue, Donohue, Donohue, Donohue, Donohue, Dransfield, Dunn, Dusser, Dusser, Dusser, Earnshaw, Eden, Edin, Effing, Eichenhorn, Fang, Fattore, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferreira, Freeman, Freeman, Friedman, Frith, Fukuchi, Fukuchi, Geake, Gelb, Gizycki, Glaab, Greefhorst, Greefhorst, Greefhorst, Gross, Grunsven, Grunsven, Guenette, Halpin, Halpin, Halpin, Hanania, Hanania, Hanania, Hanania, Hanrahan, Hanrahan, Hanrahan, Hanrahan, Hanrahan, Hattotuwa, Hettle, Hodder, Hogan, Hoogendoorn, Horstman, Houghton, Hunjan, Hunjan, Hutchinson, Inoue, Janssens, Jarad, Jenkins, Jenkins, Johansson, John, Johnell, Johnson, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Kaptein, Kardos, Kardos, Karner, Karner, Karner, Karner, Kato, Keene, Kerstjens, Kerstjens, Kerstjens, Kerstjens, Kerstjens, Kerstjens, Kerwin, Kerwin, Kerwin, Kerwin, Kerwin, Kerwin, Kesten, Kesten, Kesten, Kew, Kew, Khamis, Korenblat, Kornmann, Kornmann, Kristufek, Kristufek, Kristufek, Kunz, Lacasse, Langley, Lapperre, Laties, Littner, Llewellyn-Jones, Lofdahl, Lofdahl, Lofdahl, Lofdahl, Loke, Loppow, Lu, Lung Health Study Research Group, Löfdahl, Magnussen, Mahler, Mahler, Mahler, Mahler, Mahler, Mahler, Mahler, Mahler, Mahmud, Martinez, Matiz-Bueno, Matiz-Bueno, McDonough, McGarvey, McGarvey, McGarvey, Meer Regina, Mirici, Moen, Moita, Moita, Morice, Morice, Nannini, Nannini, Nannini, Nelson, Nelson, Nelson, Nelson, Nelson, Niewoehner, Niewoehner, Nishimura, Nitschmann, Noppen, O'Donnell, Ohar, Osztovits, Overbeek, Ozol, Ozol, Paggiaro, Paggiaro, Paggiaro, Paggiaro, Pauwels, Pauwels, Pauwels, Powrie, Powrie, Puhan, Puhan, Qiu, Qiu, Rabe, Renkema, Renkema, Rennard, Rennard, Rennard, Rennard, Rennard, Rennard, Rennard, Rennard, Rice, Rizzato, Robertson, Rodrigo, Rodrigo, Rodriguez Gonzalez-Moro, Rossi, Rutgers, Rutten-van Molken, Rutten-van Molken, Rutten-van Mölken, Rutten-van Mölken, Rutten-van Mölken, Sacchetta, Scanlon, Schermer, Sciurba, Sciurba, Scott, Scott, Seemungal, Seemungal, Senderovitz, Senderovitz, Serby, Sestini, Shaker, Shaker, Sharafkhaneh, Sharafkhaneh, Sharafkhaneh, Sin, Sin, Singh, Singh, Singh, Southard, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spiegelhalter, Stockley, Sun, Szafranski, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Thompson, Thompson, To, Tonnei, Tonnel, Troosters, Troosters, Valk, Verhoeven, Verhoeven, Verhoeven, Verhoeven, Verhoeven, Verkindre, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Vogelmeier, Vogelmeier, Vogelmeier, Vogelmeier, Vogelmeier, Vogelmeier, Voshaar, Voshaar, Wadbo, Watkins, Wedzicha, Wedzicha, Wedzicha, Wedzicha, Wedzicha, Weel, Weiner, Weiner, Weir, Weir, Weir, Weir, Welsh, Welte, Welte, Welte, Welte, Welte, Wempe, Wouters, Yan, Yang, Yildiz, Zaniolo, Zheng, Zheng, Zhong, Zhong, Zhong, Zu Wallack, ZuWallack   +511 more
core   +1 more source

Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease (Review) [PDF]

, 2011
Background The long-acting bronchodilator tiotropium and single inhaler combination therapy of inhaled corticosteroids and long-acting beta(2)-agonists are both commonly used for maintenance treatment of chronic obstructive pulmonary disease.
Appleton, Barr, Beeh, Effing, Fang, Lacasse, Nannini, Nannini, Nannini, Welsh, Yang   +10 more
core   +1 more source

Characteristics of induced sputum neutrophils and macrophages in patients with chronic obstructive pulmonary disease on a basic therapy

Бюллетень сибирской медицины, 2011
Aim of the research — to define the tiotropium bromide influence on bronchial neutrophiles and macrophages morphofunctional properties at stable of chronic obstructive pulmonary disease (COPD).
S. V. Fedosenko, G. E. Chernogoryuk, N. A. Kirillova, A. Yu. Fisenko, Ye. P. Roslyakova   +4 more
doaj   +1 more source